Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
49 hedge funds and large institutions have $42.5M invested in Viracta Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 4 closing their positions.
319% more call options, than puts
Call options by funds: $134K | Put options by funds: $32K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
60% more capital invested
Capital invested by funds: $26.6M → $42.5M (+$15.9M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
9% more funds holding
Funds holding: 45 → 49 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$5.73M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.67M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$2.23M |
| 4 |
ACM
Aisling Capital Management
New York
|
+$2.06M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.21M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$475K |
| 3 |
First Eagle Investment Management
New York
|
-$214K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$186K |
| 5 |
Renaissance Technologies
New York
|
-$143K |
VIRX Hedge Fund Activity: Q3 2019 in Review
49 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2019, worth a combined $42.5M — up 60% from $26.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VIRX positions and 4 closed out — a net gain of 4 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $5.73M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.21M sold.
- 49 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2019, up from 45 in Q2 2019.
- Funds reported $42.5M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2019, up 60% quarter-over-quarter.
- 8 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2019 and 4 closed out, a net change of +4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2019 was RTW Investments, an estimated $5.73M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2019 was Balyasny Asset Management, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2019.